Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Therapeutics

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for obsessive-compulsive disorder (OCD) and social anxiety disorder (SAD).
• Fluvoxamine has established efficacy for both OCD and SAD.
• A controlled-release (CR) formulation of fluvoxamine is now available in the US for these conditions.

Purpose of the Study:

• To evaluate the efficacy and safety of fluvoxamine CR in treating OCD and SAD.
• To compare the efficacy of fluvoxamine CR to its immediate-release (IR) counterpart.
• To assess the maintenance of efficacy and safety of fluvoxamine CR during extended treatment.

Main Methods:

• Three 12-week, double-blind, randomized, placebo-controlled trials were conducted (two in SAD, one in OCD) using fluvoxamine CR.
• One trial included a 12-week double-blind extension phase to assess long-term effects.
• Efficacy and adverse events were systematically monitored and compared between treatment groups.

Main Results:

• All three studies demonstrated robust efficacy of fluvoxamine CR on core symptoms of OCD and SAD.
• Efficacy was comparable to previously observed results with fluvoxamine IR.
• The CR formulation showed sustained benefits during the extension trial.
• Fluvoxamine CR offered reduced daily fluctuations in drug levels and allowed for faster titration compared to IR.

Conclusions:

• Fluvoxamine CR is an effective treatment for OCD and SAD.
• The CR formulation provides benefits such as once-daily dosing and potentially faster onset of action without increasing adverse events compared to the IR form.
• Fluvoxamine CR represents a valuable therapeutic option for patients with OCD and SAD.